NCT07463521 2026-03-17
MyVision
UCB Pharma
Phase 3 Not yet recruiting
Clinical Trials
90 trialsNCT06607627 2026-03-16
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06987539 2026-03-16
THYME
Amgen
Phase 2 Recruiting
NCT05265273 2026-03-13
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3 Recruiting
NCT06435312 2026-03-13
ziMyG+
UCB Pharma
Phase 3 Enrolling by invitation
NCT07217587 2026-03-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07246564 2026-03-13
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07465289 2026-03-11
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
UCB Pharma
Phase 3 Not yet recruiting
NCT04524273 2026-03-10
MINT
Amgen
Phase 3 Active not recruiting
NCT06414954 2026-03-10
SYNAPSE-MG
NMD Pharma A/S
Phase 2 Recruiting
NCT06456580 2026-03-10
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
Phase 3 Recruiting
NCT07304154 2026-03-10
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Not yet recruiting
NCT05403541 2026-03-06
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07221838 2026-03-03
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4 Not yet recruiting
NCT06463587 2026-03-02
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT06055959 2026-02-27
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-02-27
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06540144 2026-02-27
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Enrolling by invitation
NCT06680037 2026-02-27
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT06626919 2026-02-25
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Arcellx, Inc.
Phase 1 Recruiting
NCT06517758 2026-02-24
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06744920 2026-02-20
RELIEVE
Novartis
Phase 3 Recruiting
NCT05644561 2026-02-19
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04833894 2026-02-18
ADAPT Jr
argenx
Phase 2/3 Recruiting
NCT05070858 2026-02-12
NIMBLE
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06965309 2026-02-12
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase NA Terminated
NCT07250750 2026-02-11
Synergy-MG
ImmunAbs Inc.
Phase 1/2 Recruiting
NCT06220201 2026-02-10
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT07284420 2026-02-09
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT06704269 2026-02-05
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT05374590 2026-02-02
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT06193889 2026-01-30
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting
NCT05556096 2026-01-23
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed
NCT06764160 2026-01-15
ECU-MG-304
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT07249632 2026-01-15
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT05150210 2025-12-23
SP Thoracic IDE Study
Intuitive Surgical
Phase NA Active not recruiting
NCT06558279 2025-12-15
ADAPT oculus
argenx
Phase 3 Active not recruiting
NCT06392386 2025-12-05
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT07243366 2025-11-21
Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis
Guangdong ProCapZoom Biosciences Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
NCT07215650 2025-11-17
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Candid Therapeutics
Phase 1 Recruiting
NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
NCT05681715 2025-11-06
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
UCB Pharma
Phase 3 Completed
NCT04980495 2025-11-05
ADAPT NXT
argenx
Phase 3 Completed
NCT06282159 2025-10-07
MAGIC
Dianthus Therapeutics
Phase 2 Active not recruiting
NCT06471361 2025-09-26
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT04226170 2025-09-11
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
DAS-MG, Inc
Phase 2 Terminated
NCT05132569 2025-09-09
URSA
Sanofi
Phase 3 Terminated
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed